Diabetic Neuropathic Pain Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 25 23:43 2023
Diabetic Neuropathic Pain Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Diabetic Neuropathic Pain Pipeline Insights
DelveInsight’s ‘Diabetic Neuropathic Pain Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Neuropathic Pain therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Neuropathic Pain pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Diabetic Neuropathic Pain Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Neuropathic Pain therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Neuropathic Pain pipeline domain.

Key Takeaways from the Diabetic Neuropathic Pain Pipeline Report

  • Leading Diabetic Neuropathic Pain companies developing novel drug candidates to improve the Diabetic Neuropathic Pain treatment landscape include AstraZeneca, Centrexion Therapeutics, Aptinyx, and others.
  • Promising Diabetic Neuropathic Pain pipeline therapies in various stages of development include MEDI 7352, CNTX6016, NYX2925, and others.

Diabetic Neuropathic Pain Overview

Diabetic neuropathic pain is a well-known complication of diabetes and the most common cause of all neuropathic pain. About one-third of all diabetes patients suffer from DNP. It is defined as the presence of signs and/or symptoms of nerve dysfunction in patients with diabetes after exclusion of other causes. Prolonged high blood sugar (glucose) level can injure nerves throughout your body however, legs and feet are the most affected by DNP. 

The Diabetic neuropathic pain (DNP) is characterized by tingling, burning, sharp, shooting, and lancinating or even as electric shock sensations. It is usually considered moderate to severe and often worse at night, causing sleeping disturbance. The pain can be constant and accompanied of cutaneous allodynia, which can substantially affect the quality of life of patients, impacting the ability to perform daily activities and having a negative influence on mood. The pain may also be a reason of withdrawal of recreational and social activities and may be associated with depression.

Diabetic Neuropathic Pain Pipeline Analysis: Drug Profile

MEDI 7352- AstraZeneca

MEDI 7352 is an NGF/TNF bispecific mAb. Bispecific antibodies are artificial proteins. They comprise of two monoclonal antibodies held together by a flexible peptide linker. As the name suggests, this helps them bind to two different antigens. It involves investigating the effect of MEDI7352 on chronic pain in patients with painful diabetic neuropathy.

It is currently in Phase II clinical trial to  study of the efficacy and safety of MEDI7352 in subjects with Painful Diabetic Neuropathy.

Discover more about the emerging Diabetic Neuropathic Pain drugs @ Diabetic Neuropathic Pain Treatment Drugs

Diabetic Neuropathic Pain Key Companies

  • AstraZeneca
  • Centrexion Therapeutics
  • Aptinyx

Diabetic Neuropathic Pain Pipeline Therapies

  • MEDI 7352
  • CNTX6016
  • NYX2925

Diabetic Neuropathic Pain Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Diabetic Neuropathic Pain Pipeline Report 

  • Coverage: Global 
  • Key Diabetic Neuropathic Pain Companies: AstraZeneca, Centrexion Therapeutics, Aptinyx, and others
  • Key Diabetic Neuropathic Pain Pipeline Therapies: MEDI 7352, CNTX6016, NYX2925, and others

Find out more about the Diabetic Neuropathic Pain treatment options in development @ Diabetic Neuropathic Pain Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Diabetic Neuropathic Pain pipeline segment.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/